The 2024 child and adolescent immunization schedule includes the addition of the respiratory syncytial virus (RSV) vaccine, respiratory syncytial virus monoclonal antibody, Mpox vaccine, 20-valent pneumococcal conjugate vaccine, and pentavalent meningococcal vaccine.
More than 6.5 million topical antifungal prescriptions (costing $231 million) were filled in 2021 by Medicare Part D beneficiaries and nearly half of those prescriptions were written by 10% of topical antifungal prescribers.
The 2024 adult immunization schedule includes the addition of the respiratory syncytial virus (RSV) vaccine, Mpox vaccine, a new pentavalent meningococcal vaccine, the updated (2023-24 formula) COVID-19 vaccine, flu vaccine, and inactivated poliovirus vaccine.
Adults on dialysis with Medicare and adults aged 65 and older with Medicare who received a bivalent COVID-19 vaccine during September 2022-March 2023 were about 50% less likely to have a COVID-19-associated stroke, blood clot, or heart attack compared with those who received only the original monovalent COVID-19 vaccine.
The latest MMWR Weekly Briefing is live. Topics include: COVID-19 rebound, COVID-19 and RSV vaccination coverage among nursing home residents, and more. Listen and subscribe on: Apple Podcasts, Spotify, and Google Play.
